This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Greatbatch, Inc. Reports 2012 Fourth Quarter And Full Year Results

Financial Guidance

As previously disclosed, for 2013, Greatbatch estimates annual revenue growth rates for its product lines as follows:

Product Line   Estimated 2013 Annual Growth Rate (%)   2013 Estimated Revenue

(millions)

Cardiac & Neuromodulation   0% - 2%   $309 - $315
Vascular 7% - 13% $55 - $59
Orthopaedic (1) (5%) - 0% $116 - $122
Portable Medical 15% - 20% $94 - $98
Energy & Other   6%   $86 - $86
Total Sales (1)   2% - 5%   $660 - $680
(1)   Organic revenue growth for orthopaedic product line is 8% - 14% due to disposition of $15 million of non-core product lines at the end of 2012. Total consolidated organic revenue growth is expected to be 5% - 8%.

Adjusted Operating Income as a % of Sales   12.0% - 12.5%
Adjusted Effective Tax Rate (includes only the 2013 benefit of the recently reenacted U.S. R&D Tax Credit)

 

33% to 35%

Adjusted Diluted EPS $ 1.90 - $2.00

As previously disclosed, adjusted operating income for 2013 is expected to consist of GAAP operating income minus non-recurring, unusual or infrequently occurring items such as acquisition, consolidation and integration charges, certain RD&E expenditures and asset disposition/write-down charges, totaling approximately $11.5 million to $14.0 million. This range has been significantly reduced from the 2012 level as we have essentially completed our productivity and consolidation initiatives. Included in the above range are residual DVT costs in the range of $4.8 to $5.8 million to complete our Algostim project.

8 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,963.86 -74.11 -0.41%
S&P 500 2,098.79 -10.13 -0.48%
NASDAQ 5,019.0170 -41.2290 -0.81%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs